Cargando…

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity

CONTEXT: Treatment of advanced and recurrent endometrial cancer (EC) is still an unmet need for oncologists and gynecologic oncologists. The Cancer Genome Atlas Research Network (TCGA) recently provided a new genomic classification, dividing EC in four subgroups. Two types of EC, the polymerase epsi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mittica, Gloria, Ghisoni, Eleonora, Giannone, Gaia, Aglietta, Massimo, Genta, Sofia, Valabrega, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685772/ https://www.ncbi.nlm.nih.gov/pubmed/29163851 http://dx.doi.org/10.18632/oncotarget.20042

Ejemplares similares

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
por: Mittica, Gloria, et al.
Publicado: (2016)

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
por: Giannone, Gaia, et al.
Publicado: (2019)

Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020)

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
por: Giannone, Gaia, et al.
Publicado: (2020)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2020)

Androgen receptor status predicts development of brain metastases in ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2017)

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
por: Capellero, S., et al.
Publicado: (2020)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Ovarian Cancer Immunotherapy: Turning up the Heat
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer
por: Erriquez, Jessica, et al.
Publicado: (2016)

Recent advances in the development of breast cancer vaccines
por: Milani, Andrea, et al.
Publicado: (2014)

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
por: Tuninetti, Valentina, et al.
Publicado: (2020)

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
por: Virtanen, Verneri, et al.
Publicado: (2019)

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
por: Granier, Clemence, et al.
Publicado: (2017)

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
por: Gong, Jun, et al.
Publicado: (2019)

Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
por: Hwang, June Kyu, et al.
Publicado: (2020)

Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
por: Giannone, Gaia, et al.
Publicado: (2022)

Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
por: Antill, Yoland, et al.
Publicado: (2021)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
por: Taghizadeh, H., et al.
Publicado: (2019)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice
por: Lasorsa, Francesco, et al.
Publicado: (2023)

Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
por: Scotto, Giulia, et al.
Publicado: (2021)

Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies
por: Singla, Rajeev K., et al.
Publicado: (2022)

Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective
por: Donini, Chiara, et al.
Publicado: (2021)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)

Checkpoint inhibitors in ovarian cancer: A review of preclinical data
por: Doo, David W., et al.
Publicado: (2019)

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
por: Mecca, Carmen, et al.
Publicado: (2018)

Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2022)

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience
por: Tuninetti, Valentina, et al.
Publicado: (2023)

Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer
por: Arora, Ena, et al.
Publicado: (2018)

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
por: Ott, Patrick A., et al.
Publicado: (2015)

Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy
por: Rotolo, Ramona, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vs3jajvv9e4flcnoclojqh24vv